Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.

Ponnusamy S, He Y, Hwang DJ, Thiyagarajan T, Houtman R, Bocharova V, Sumpter BG, Fernandez E, Johnson D, Du Z, Pfeffer LM, Getzenberg RH, McEwan IJ, Miller DD, Narayanan R.

Clin Cancer Res. 2019 Sep 3. doi: 10.1158/1078-0432.CCR-19-1458. [Epub ahead of print]

PMID:
31481513
2.

Hormone levels following surgical and medical castration: defining optimal androgen suppression.

Schweizer MT, Hancock ML, Getzenberg RH, Yu EY.

Asian J Androl. 2018 Jul-Aug;20(4):405-406. doi: 10.4103/aja.aja_38_17. No abstract available.

3.

Tissue Selective Androgen Receptor Modulators (SARMs) Increase Pelvic Floor Muscle Mass in Ovariectomized Mice.

Ponnusamy S, Sullivan RD, Thiyagarajan T, Tillmann H, Getzenberg RH, Narayanan R.

J Cell Biochem. 2017 Mar;118(3):640-646. doi: 10.1002/jcb.25751. Epub 2016 Nov 28.

PMID:
27681158
4.

Disorder, Promiscuous Interactions, and Stochasticity Regulate State Switching in the Unstable Prostate.

Kulkarni P, Getzenberg RH.

J Cell Biochem. 2016 Oct;117(10):2235-40. doi: 10.1002/jcb.25578. Epub 2016 Jun 3. Review.

PMID:
27152744
5.

Downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer.

Yin B, Zhang M, Zeng Y, Li Y, Zhang C, Getzenberg RH, Song Y.

Int J Oncol. 2016 Apr;48(4):1730-6. doi: 10.3892/ijo.2016.3396. Epub 2016 Feb 17. Erratum in: Int J Oncol. 2016 Aug;49(2):848. Getzenberg, Robert H [added].

PMID:
26892177
6.

Nanowire analysis of cancer-testis antigens as biomarkers of aggressive prostate cancer.

Takahashi S, Shiraishi T, Miles N, Trock BJ, Kulkarni P, Getzenberg RH.

Urology. 2015 Mar;85(3):704.e1-7. doi: 10.1016/j.urology.2014.12.004.

7.

The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.

Liu Z, Zhu G, Getzenberg RH, Veltri RW.

J Cell Biochem. 2015 Jul;116(7):1341-9. doi: 10.1002/jcb.25091.

PMID:
25640606
8.

Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder.

McNeil BK, Sorbellini M, Grubb RL 3rd, Apolo A, Cecchi F, Athauda G, Cohen B, Giubellino A, Simpson H, Agarwal PK, Coleman J, Getzenberg RH, Netto GJ, Shih J, Linehan WM, Pinto PA, Bottaro DP.

J Transl Med. 2014 Oct 21;12:199. doi: 10.1186/1479-5876-12-199.

9.

Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer.

Yu EY, Getzenberg RH, Coss CC, Gittelman MM, Keane T, Tutrone R, Belkoff L, Given R, Bass J, Chu F, Gambla M, Gaylis F, Bailen J, Hancock ML, Smith J, Dalton JT, Steiner MS.

Eur Urol. 2015 Feb;67(2):334-41. doi: 10.1016/j.eururo.2014.06.011. Epub 2014 Jun 24.

PMID:
24968970
10.

Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation.

Terada N, Shiraishi T, Zeng Y, Aw-Yong KM, Mooney SM, Liu Z, Takahashi S, Luo J, Lupold SE, Kulkarni P, Getzenberg RH.

J Cell Biochem. 2014 Sep;115(9):1505-15. doi: 10.1002/jcb.24805.

11.

Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen.

Mukherjee A, Darlington T, Baldwin R, Holz C, Olson S, Kulkarni P, DeWeese TL, Getzenberg RH, Ivkov R, Lupold SE.

ChemMedChem. 2014 Jul;9(7):1356-60. doi: 10.1002/cmdc.201300549. Epub 2014 Mar 3.

12.

Monitoring nanoparticle-mediated cellular hyperthermia with a high-sensitivity biosensor.

Mukherjee A, Castanares M, Hedayati M, Wabler M, Trock B, Kulkarni P, Rodriguez R, Getzenberg RH, DeWeese TL, Ivkov R, Lupold SE.

Nanomedicine (Lond). 2014 Dec;9(18):2729-43. doi: 10.2217/nnm.13.207.

13.

Retraction: Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology.

Myers-Irvin JM, Getzenberg RH.

Cancer Res. 2014 Feb 1;74(3):974. doi: 10.1158/0008-5472.CAN-13-3721. No abstract available.

14.

Tools to identify the men with prostate cancer most appropriate for active surveillance?

Getzenberg RH.

Asian J Androl. 2014 Jan-Feb;16(1):97-8. doi: 10.4103/1008-682X.122369. No abstract available.

15.

Morphological effects on expression of growth differentiation factor 15 (GDF15), a marker of metastasis.

Aw Yong KM, Zeng Y, Vindivich D, Phillip JM, Wu PH, Wirtz D, Getzenberg RH.

J Cell Physiol. 2014 Mar;229(3):362-73. doi: 10.1002/jcp.24458.

16.

Retraction: Functional characterization of the bladder cancer marker, BLCA-4.

Van Le TS, Myers J, Getzenberg RH, Konety BR, Barder T.

Clin Cancer Res. 2013 Jun 15;19(12):3327. doi: 10.1158/1078-0432.CCR-13-1145. Epub 2013 May 24. No abstract available.

17.

Stress-response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing.

Zeng Y, Wodzenski D, Gao D, Shiraishi T, Terada N, Li Y, Vander Griend DJ, Luo J, Kong C, Getzenberg RH, Kulkarni P.

Cancer Res. 2013 Jul 1;73(13):4123-33. doi: 10.1158/0008-5472.CAN-12-1343. Epub 2013 May 10.

18.

DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases.

Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, Luo J, Xu J, Isaacs WB, Bova GS, Yegnasubramanian S.

Sci Transl Med. 2013 Jan 23;5(169):169ra10. doi: 10.1126/scitranslmed.3005211.

19.

Prostate-associated gene 4 (PAGE4) protects cells against stress by elevating p21 and suppressing reactive oxygen species production.

Zeng Y, Gao D, Kim JJ, Shiraishi T, Terada N, Kakehi Y, Kong C, Getzenberg RH, Kulkarni P.

Am J Clin Exp Urol. 2013 Dec 25;1(1):39-52. eCollection 2013.

20.

Retraction: Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer.

Schoen RE, Magheli A, Sokoll LJ, Chan DW, Getzenberg RH.

Clin Cancer Res. 2013 Jan 15;19(2):508. doi: 10.1158/1078-0432.CCR-12-2711. Epub 2012 Dec 27.

21.

Retraction. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers.

Schoen RE, Weissfeld JL, Sokoll LJ, Chan DW, Cannon GW, Getzenberg RH.

Cancer Res. 2013 Jan 15;73(2):1034. doi: 10.1158/0008-5472.CAN-12-3286. Epub 2012 Dec 27. No abstract available.

22.

Intrinsically disordered proteins and conformational noise: implications in cancer.

Mahmoudabadi G, Rajagopalan K, Getzenberg RH, Hannenhalli S, Rangarajan G, Kulkarni P.

Cell Cycle. 2013 Jan 1;12(1):26-31. doi: 10.4161/cc.23178. Epub 2012 Dec 19.

23.

Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer.

Kim JJ, Yin B, Christudass CS, Terada N, Rajagopalan K, Fabry B, Lee DY, Shiraishi T, Getzenberg RH, Veltri RW, An SS, Mooney SM.

J Cell Biochem. 2013 Jun;114(6):1286-93. doi: 10.1002/jcb.24464.

24.

Circulating fibroblast-like cells in men with metastatic prostate cancer.

Jones ML, Siddiqui J, Pienta KJ, Getzenberg RH.

Prostate. 2013 Jan;73(2):176-81. doi: 10.1002/pros.22553. Epub 2012 Jun 21.

25.

Cancer/testis antigens and urological malignancies.

Kulkarni P, Shiraishi T, Rajagopalan K, Kim R, Mooney SM, Getzenberg RH.

Nat Rev Urol. 2012 Jun 19;9(7):386-96. doi: 10.1038/nrurol.2012.117. Review.

26.

Helping to address the over treatment of prostate cancer: tools to differentiate lethal and non-lethal phenotype in prostate cancer.

Getzenberg RH, Carter HB.

Asian J Androl. 2012 May;14(3):347-8. doi: 10.1038/aja.2012.34. Epub 2012 Apr 23. No abstract available.

27.

Cancer/testis antigens: novel tools for discerning aggressive and non-aggressive prostate cancer.

Shiraishi T, Getzenberg RH, Kulkarni P.

Asian J Androl. 2012 May;14(3):400-4. doi: 10.1038/aja.2011.144. Epub 2012 Feb 20. Review.

28.

Cyr61 is a potential prognostic marker for prostate cancer.

Terada N, Kulkarni P, Getzenberg RH.

Asian J Androl. 2012 May;14(3):405-8. doi: 10.1038/aja.2011.149. Epub 2012 Feb 20. Review.

29.

A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients.

Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby JE, Hohl R, Bailey H.

Cancer Prev Res (Phila). 2012 Apr;5(4):621-30. doi: 10.1158/1940-6207.CAPR-11-0455. Epub 2012 Jan 31.

30.

Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness.

Terada N, Shiraishi T, Zeng Y, Mooney SM, Yeater DB, Mangold LA, Partin AW, Kulkarni P, Getzenberg RH.

Prostate. 2012 Jun 15;72(9):966-76. doi: 10.1002/pros.21501. Epub 2011 Oct 24.

31.

Changing the energy habitat of the cancer cell in order to impact therapeutic resistance.

Getzenberg RH, Coffey DS.

Mol Pharm. 2011 Dec 5;8(6):2089-93. doi: 10.1021/mp200310u. Epub 2011 Sep 29. Review.

32.

Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy.

Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J, Trock B, Kulkarni P, Getzenberg RH.

J Transl Med. 2011 Sep 14;9:153. doi: 10.1186/1479-5876-9-153.

33.

A majority of the cancer/testis antigens are intrinsically disordered proteins.

Rajagopalan K, Mooney SM, Parekh N, Getzenberg RH, Kulkarni P.

J Cell Biochem. 2011 Nov;112(11):3256-67. doi: 10.1002/jcb.23252.

34.

Probing the invasiveness of prostate cancer cells in a 3D microfabricated landscape.

Liu L, Sun B, Pedersen JN, Aw Yong KM, Getzenberg RH, Stone HA, Austin RH.

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):6853-6. doi: 10.1073/pnas.1102808108. Epub 2011 Apr 7.

35.

Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells.

Li Y, Zeng Y, Mooney SM, Yin B, Mizokami A, Namiki M, Getzenberg RH.

J Cell Biochem. 2011 Aug;112(8):2125-37. doi: 10.1002/jcb.23134.

36.

Protein folding and the order/disorder paradox.

Kulkarni P, Rajagopalan K, Yeater D, Getzenberg RH.

J Cell Biochem. 2011 Jul;112(7):1949-52. doi: 10.1002/jcb.23115.

37.

The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein.

Zeng Y, He Y, Yang F, Mooney SM, Getzenberg RH, Orban J, Kulkarni P.

J Biol Chem. 2011 Apr 22;286(16):13985-94. doi: 10.1074/jbc.M110.210765. Epub 2011 Feb 25.

38.

Prostate cancer-derived angiogenin stimulates the invasion of prostate fibroblasts.

Jones ML, Ewing CM, Isaacsa WB, Getzenberg RH.

J Cell Mol Med. 2012 Jan;16(1):193-201. doi: 10.1111/j.1582-4934.2011.01283.x.

39.

Creatine kinase brain overexpression protects colorectal cells from various metabolic and non-metabolic stresses.

Mooney SM, Rajagopalan K, Williams BH, Zeng Y, Christudass CS, Li Y, Yin B, Kulkarni P, Getzenberg RH.

J Cell Biochem. 2011 Apr;112(4):1066-75. doi: 10.1002/jcb.23020.

40.

Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment.

D'Antonio KB, Schultz L, Albadine R, Mondul AM, Platz EA, Netto GJ, Getzenberg RH.

Clin Cancer Res. 2010 Dec 1;16(23):5908-13. doi: 10.1158/1078-0432.CCR-10-1200.

41.

Novel approaches for the molecular classification of prostate cancer.

Getzenberg RH.

Asian J Androl. 2010 Sep;12(5):620-2. doi: 10.1038/aja.2010.95. Epub 2010 Aug 16. No abstract available.

42.

Statins and the risk of prostate cancer or benign prostatic hyperplasia: biological plausibility.

Getzenberg RH.

J Urol. 2010 Aug;184(2):415-6. doi: 10.1016/j.juro.2010.05.045. Epub 2010 Jun 17. No abstract available.

PMID:
20620390
43.

Expression of cancer/testis antigens in prostate cancer is associated with disease progression.

Suyama T, Shiraishi T, Zeng Y, Yu W, Parekh N, Vessella RL, Luo J, Getzenberg RH, Kulkarni P.

Prostate. 2010 Dec 1;70(16):1778-87. doi: 10.1002/pros.21214.

44.

A microfluidic device for continuous cancer cell culture and passage with hydrodynamic forces.

Liu L, Loutherback K, Liao D, Yeater D, Lambert G, Estévez-Torres A, Sturm JC, Getzenberg RH, Austin RH.

Lab Chip. 2010 Jul 21;10(14):1807-13. doi: 10.1039/c003509b. Epub 2010 Apr 27.

45.

Extracellular matrix associated protein CYR61 is linked to prostate cancer development.

D'Antonio KB, Toubaji A, Albadine R, Mondul AM, Platz EA, Netto GJ, Getzenberg RH.

J Urol. 2010 Apr;183(4):1604-10. doi: 10.1016/j.juro.2009.12.006. Epub 2010 Feb 20.

46.

Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia.

Fujita K, Ewing CM, Getzenberg RH, Parsons JK, Isaacs WB, Pavlovich CP.

Prostate. 2010 Apr 1;70(5):473-81. doi: 10.1002/pros.21081.

47.

Identification of nuclear structural protein alterations associated with seminomas.

Leman ES, Magheli A, Yong KM, Netto G, Hinz S, Getzenberg RH.

J Cell Biochem. 2009 Dec 15;108(6):1274-9. doi: 10.1002/jcb.22357.

PMID:
19795381
48.

Biomarkers for prostate cancer.

Leman ES, Getzenberg RH.

J Cell Biochem. 2009 Sep 1;108(1):3-9. doi: 10.1002/jcb.22227. Review.

PMID:
19507229
49.

Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2.

Leman ES, Magheli A, Cannon GW, Mangold L, Partin AW, Getzenberg RH.

Prostate. 2009 Aug 1;69(11):1188-94. doi: 10.1002/pros.20963. Retraction in: Prostate. 2012 Jul 1;72(10):1157.

50.

Urinary protein biomarkers of cancer.

McNeil BK, Getzenberg RH.

Expert Opin Med Diagn. 2009 May;3(3):263-73. doi: 10.1517/17530050902824811. Epub 2009 Apr 8.

PMID:
23488462

Supplemental Content

Loading ...
Support Center